Torrent Pharmaceuticals is currently trading at Rs. 1297.55, up by 6.55 points or 0.51% from its previous closing of Rs. 1291.00 on the BSE.
The scrip opened at Rs. 1303.75 and has touched a high and low of Rs. 1303.75 and Rs. 1296.60 respectively. So far 1683 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1767.80 on 25-Aug-2016 and a 52 week low of Rs. 1185.60 on 09-Nov-2016.
Last one week high and low of the scrip stood at Rs. 1433.80 and Rs. 1282.00 respectively. The current market cap of the company is Rs. 21846.65 crore.
The promoters holding in the company stood at 71.25%, while institutions and non-institutions held 17.60% and 11.16% respectively.
Torrent Pharmaceuticals has completed the acquisition of women healthcare brands Regestrone and Pregachieve for India from Swiss pharma major Novartis AG. The deal size is estimated to be around Rs 500 crore. Both the brands are prescribed by gynaecologists for management of abnormal uterine bleeding, peri and post menopausal symptoms and infertility.
The Ahmedabad-based company was in talks to acquire these brands since the last few months and had entered into a pact with Novartis last month to acquire the two brands.
Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: